Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | LTA4H | P09960 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13132269 | 1.00 | MEN1 (0.42) | MEN1KMT2ALTA4HSMN1; SMN2POLB | |
| SCHEMBL14435203 | 1.00 | MEN1 (0.42) | MEN1KMT2ALTA4HSMN1; SMN2POLB | |
| SCHEMBL13547722 | 0.98 | MEN1 (0.46) | MEN1KMT2ALTA4HSMN1; SMN2POLB | |
| SCHEMBL23205839 | 0.98 | MEN1 (0.46) | MEN1KMT2ALTA4HSMN1; SMN2POLB | |
| SCHEMBL13547720 | 0.81 | POLB (0.45) | MEN1KMT2ASMN1; SMN2POLBMAPT | |
| SCHEMBL9432545 | 0.79 | TLR9 (0.30) | — | |
| SCHEMBL12125079 | 0.79 | USP2 (0.50) | MEN1KMT2ASMN1; SMN2USP2TSHR | |
| SCHEMBL20349515 | 0.79 | DRD2 (0.33) | SMN1; SMN2POLB | |
| SCHEMBL23205826 | 0.79 | USP2 (0.50) | MEN1KMT2ASMN1; SMN2USP2TSHR | |
| SCHEMBL18390141 | 0.79 | DRD2 (0.33) | SMN1; SMN2POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2602307-B1 | LUBRICANT COMPOSITION WITH RUST INHIBITING PROPERTIES AND WITH AN IONIC LIQUID AS THE BASE OIL | KYODO YUSHI (JP) | 2017-05-10 | — | — | EP | claimed |
| EP-2602307-A1 | LUBRICANT COMPOSITION WITH EXCELLENT RUST INHIBITING PROPERTIES AND WITH AN IONIC LIQUID AS A BASE OIL | Kyodo Yushi Co., Ltd. (JP) | 2013-06-12 | — | — | EP | claimed |
| US-20130137615-A1 | LUBRICANT COMPOSITION USING IONIC LIQUID AS BASE OIL AND HAVING EXCELLENT RUST PREVENTION PROPERTIES | KYODO YUSHI CO., LTD. (JP) | 2013-05-30 | — | — | US | claimed |
| US-20230242544-A1 | QUINAZOLINE COMPOUNDS, PREPARATION METHODS AND USES THEREOF | InventisBio Co., Ltd. (CN) | 2023-08-03 | — | — | US | disclosed |
| WO-2022002102-A1 | QUINAZOLINE COMPOUNDS, PREPARATION METHODS AND USES THEREOF | InventisBio Co., Ltd. (CN) | 2022-01-06 | — | — | WO | disclosed |
| EP-3666860-A1 | ANTI-FLAKING AGENT AND LUBRICANT COMPOSITION COMPRISING THE SAME | Kyodo Yushi Co., Ltd. (JP) | 2020-06-17 | — | — | EP | disclosed |
| US-9882246-B2 | Electrochemical energy storing device | PANASONIC CORPORATION (JP) | 2018-01-30 | — | — | US | disclosed |
| EP-2602307-B1 | LUBRICANT COMPOSITION WITH RUST INHIBITING PROPERTIES AND WITH AN IONIC LIQUID AS THE BASE OIL | KYODO YUSHI (JP) | 2017-05-10 | — | — | EP | disclosed |
| CN-104756301-B | Electrochemical energy storage device | 松下电器产业株式会社 | 2017-03-01 | — | — | CN | disclosed |
| US-20150325883-A1 | ELECTROCHEMICAL ENERGY STORAGE DEVICE | KYOTO UNIVERSITY (JP) | 2015-11-12 | — | — | US | disclosed |
| US-20150255830-A1 | ELECTROCHEMICAL ENERGY STORING DEVICE | KYOTO UNIVERSITY (JP) | 2015-09-10 | — | — | US | disclosed |
| US-9012381-B2 | Lubricant composition using ionic liquid as a base oil and having excellent rust prevention properties | KYODO YUSHI CO., LTD. (JP) | 2015-04-21 | — | — | US | disclosed |
| EP-2602307-A1 | LUBRICANT COMPOSITION WITH EXCELLENT RUST INHIBITING PROPERTIES AND WITH AN IONIC LIQUID AS A BASE OIL | Kyodo Yushi Co., Ltd. (JP) | 2013-06-12 | — | — | EP | disclosed |
| US-20130137615-A1 | LUBRICANT COMPOSITION USING IONIC LIQUID AS BASE OIL AND HAVING EXCELLENT RUST PREVENTION PROPERTIES | KYODO YUSHI CO., LTD. (JP) | 2013-05-30 | — | — | US | disclosed |
| US-20110086836-A1 | Substituted Phenylpiperidine Derivatives As Melanocortin-4 Receptor Modulators | SANTHERA PHARMACEUTICALS (SCHWEIZ) AG (CH) | 2011-04-14 | — | — | US | disclosed |
| US-20110086836-A1 | Substituted Phenylpiperidine Derivatives As Melanocortin-4 Receptor Modulators | SANTHERA PHARMACEUTICALS (SCHWEIZ) AG (CH) | 2011-04-14 | — | — | US | disclosed |
| US-7652051-B2 | Heterocyclic compounds and methods of use | TARGEGEN, INC. (US) | 2010-01-26 | — | — | US | disclosed |
| JP-2005012069-A | ELECTROLYTE FOR DRIVING ELECTROLYTIC CAPACITOR | NICHICON CORP | 2005-01-13 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230242544-A1 | QUINAZOLINE COMPOUNDS, PREPARATION METHODS AND USES THEREOF | KRAS, NRAS, HRAS | MEN1 80/4885KMT2A 1113/4885LTA4H 4321/4885 |
| US-20110086836-A1 | Substituted Phenylpiperidine Derivatives As Melanocortin-4 Receptor Modulators | MC4R, MC5R, MC3R | MEN1 1627/4885KMT2A 855/4885LTA4H 2046/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.